Ms. Simpson has over two decades of drug development strategy experience across a diverse group of organizations: from seed investments to public companies. Throughout her career, Camilla has demonstrated a proven track record in delivering novel products for multiple disease indications to global markets in areas of high unmet medical need. Currently, Camilla is the Managing Member and President of Rare Strategic, LLC, where she provides strategic advice to early stage companies. Prior to this, Camilla held numerous executive leadership positions including SVP, Head of Product Portfolio Development at BioMarin Pharmaceutical Inc., Global Head of Regulatory Affairs at BioMarin Pharmaceutical Inc., and VP Global Regulatory Strategy- Early Development and Business Development at Shire Pharmaceuticals. Ms. Simpson serves on the Board of Directors of Spruce Biosciences and Dyve Biosciences. Camilla has also been a member of the Scientific Advisory Board of Aristea Therapeutics since November 2019. Ms. Simpson received a BSc from National University of Ireland, Galway, a BSc Hons, from Kingston University, UK and a MSc with distinction, from Birkbeck College, University of London.
© Copyright AceLink Therapeutics. All rights reserved